Science review: The use of proton pump inhibitors for gastric acid suppression in critical illness

Critical Care

Volumn 9, Issue 1, 2005, Pages 45-50

  Brett, Stephen ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Histamine H2 receptor antagonists; Intensive care units; Omeprazole; Pantoprazole; Proton pump inhibitors

Indexed keywords

ANTACID AGENT; CIMETIDINE; CIPROFLOXACIN; DIAZEPAM; DIGOXIN; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; IMIPRAMINE; LANSOPRAZOLE; LIDOCAINE; METRONIDAZOLE; MIDAZOLAM; NIFEDIPINE; NIZATIDINE; NORFLOXACIN; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; PROPRANOLOL; PROTON PUMP INHIBITOR; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RABEPRAZOLE; RANITIDINE; STOMACH SECRETION INHIBITOR; SUCRALFATE; THEOPHYLLINE; WARFARIN;

ALUMINUM OVERLOAD; BEZOAR; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; CRITICAL ILLNESS; DIARRHEA; DIZZINESS; DRUG ADMINISTRATION ROUTE; DRUG ANTAGONISM; DRUG BINDING; DRUG CHOICE; DRUG HALF LIFE; DRUG USE; ELECTROLYTE DISTURBANCE; ENTERIC FEEDING; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPOPHOSPHATEMIA; INTENSIVE CARE UNIT; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; LIVER DISEASE; LIVER DYSFUNCTION; MEDICAL DECISION MAKING; NAUSEA; PEPTIC ULCER; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PRURITUS; REVIEW; STOMACH ACID SECRETION; STOMACH PH; STOMACH ULCER; STRESS RELATED MUCOSAL DAMAGE; STRESS ULCER; TACHYPHYLAXIS; THROMBOCYTOPENIA; ZOLLINGER ELLISON SYNDROME;

ANTI-ULCER AGENTS; CRITICAL CARE; DRUG INTERACTIONS; GASTRIC ACID; GASTRITIS; HISTAMINE H2 ANTAGONISTS; HUMANS; PEPTIC ULCER; PROTON PUMPS;

EID: 13844266878     PISSN: 13648535     EISSN: None     Source Type: Journal    
DOI: 10.1186/cc2980     Document Type: Review

References (81)

1. Metz DC: Potential uses of intravenous proton pump inhibitors to control gastric acid secretion. Digestion 2000, 62: 73-81.
2. Fennerty MB: Pathophysiology of the upper gastrointestinal tract in the critically ill patient: rationale for the therapeutic benefits of acid suppression. Crit Care Med 2002, 30: 351-S355.
3. Cook DJ, Griffith LE, Walter SD, Guyatt GH, Meade MO, Heyland DK, Kirby A, Tryba M: The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care 2001, 5: 68-375.
4. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm 1999, 56:347-379.
5. Tryba M, Cook D: Current guidelines on stress ulcer prophylaxis. Drugs 1997, 54:581-596.
6. Institute for Healthcare Improvement: resources [http://www.ihi.org/resources/]
7. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, et al. Surviving Sepsis Campaign guidelines for the management of severe sepsis and septic shock. Intensive Care Med 2004, 4: 536-555. [www.survivingsepsis.com/treatments.html]
8. Cook D, Guyatt G, Marshall J, Leasa D, Fuller H, Hall R, Peters S, Rutledge F, Griffith L, McLellan A, et al.: A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med 1998, 338: 91-797.
9. Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S: Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on 'sepsis-related problems' of the European Society of Intensive Care Medicine. Crit Care Med 1998, 26:1793-1800.
10. Vincent JL, Moreno R, Takala J, Willatts S, de Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996, 22:707-710.
11. MacLaren R, Jarvis CL, Fish DN: Use of enteral nutrition for stress ulcer prophylaxis. Ann Pharmacother 2001, 35: 614-1623.
12. Hastings PR, Skillman JJ, Bushnell LS, Silen W: Antacid titration in the prevention of acute gastrointestinal bleeding: a controlled, randomized trial in 100 critically ill patients. N Engl J Med 1978, 298:1041-1045.
13. Aris R, Karlstadt R, Paoletti V, Blatcher B, McDevitt J: Intermittent intravenous pantoprazole achieves a similar onset time to pH > 4.0 in ICU patients as continuous infusion H2-receptor antagonist, without tolerance [abstract]. Am J Gastroenterol 2001, 96 Suppl: 147.
14. Geus WP: Are there indications for intravenous acid-inhibition in the prevention and treatment of upper GI bleeding? Scand J Gastroenterol 2000, 232 Suppl: 10-20.
15. Lam NP, Le PT, Crawford SY, Patel S: National survey of stress ulcer prophylaxis. Crit Care Med 1999, 27:98-103.
16. Smythe MA, Zarowitz BJ: Changing perspectives of stress gastritis prophylaxis. Ann Pharmacother 1994, 28: 073-1085.
17. Miller SJ, Simpson J: Medication-nutrient interactions: hypophosphatemia associated with sucralfate in the intensive care unit. Nutr Clin Pract 1991, 6:199-201.
18. Krupp KB, Johns P, Troncoso V: Esophageal bezoar formation in a tube-fed patient receiving sucralfate and antacid therapy: a case report. Gastroenterol Nurs 1995, 18:46-48.
19. Hemstreet BA: Use of sucralfate in renal failure. Ann Pharmacother 2001, 35:360-364.
20. Pai S, Melethil S, Cuddy P, Hall T: Elevation of serum aluminum in humans on a two-day sucralfate regimen. J Clin Pharmacol 1987, 27:213-215.
21. Leung AC, Henderson IS, Halls DJ, Dobbie JW: Aluminium hydroxide versus sucralfate as a phosphate binder in uraemia. Br Med J (Clin Res Ed) 1983, 286:1379-1381.
22. Robertson JA, Salusky IB, Goodman WG, Norris KC, Coburn JW: Sucralfate, intestinal aluminum absorption, and aluminum toxicity in a patient on dialysis. Ann Intern Med 1989, 111:179-181.
23. Rey AM, Gums JG: Altered absorption of digoxin, sustained-release quinidine, and warfarin with sucralfate administration. DICP 1991, 25:745-746.
24. Smart HL, Somerville KW, Williams J, Richens A, Langman MJ: The effects of sucralfate upon phenytoin absorption in man. Br J Clin Pharmacol 1985, 20:238-240.
25. Summary of product characteristics - sucralfate. http://emc.medicines.org.uk/ (last accessed 6th October 2004).
26. Bresalier RS, Grendell JH, Cello JP, Meyer AA: Sucralfate suspension versus titrated antacid for the prevention of acute stress-related gastrointestinal hemorrhage in critically ill patients. Am J Med 1987, 83:110-116.
27. Borrero E, Margolis IB, Bank S, Shulman N, Chardavoyne R: Antacid versus sucralfate in preventing acute gastrointestinal bleeding. A randomized trial in 100 critically ill patients. Am J Surg 1984, 148:809-812.
28. Somberg L, Karlstadt R, Gallagher K, McDevitt J, Graepel J, Paoletti V: Intravenous pantoprazole rapidly achieves pH greater than 4.0 in ICU patients without development of tolerance [abstract]. Gastroenterology 2001, 120:A157.
29. Huggins RM, Scates AC, Latour JK: Intravenous proton-pump inhibitors versus H2-antagonists for treatment of GI bleeding. Ann Pharmacother 2003, 37:433-437.
30. Mathot RA, Geus WP: Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: characterization of tolerance. Clin Pharmacol Ther 1999, 66:140-151.
31. Sandvik AK, Brenna E, Waldum HL: Review article: the pharmacological inhibition of gastric acid secretion - tolerance and rebound. Aliment Pharmacol Ther 1997, 11:1013-1018.
32. Merki HS, Wilder-Smith CH: Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology 1994, 106:60-64.
33. 2 antagonist-induced thrombocytopenia: is this a real phenomenon? Intensive Care Med 2002, 28:459-465.
34. Fisher AA, Le Couteur DG: Nephrotoxicity and hepatotoxicity of histamine H2 receptor antagonists. Drug Saf 2001, 24:39-57.
35. Garg DC, Baltodano N, Jallad NS, Perez G, Oster JR, Eshelman FN, Weidler DJ: Pharmacokinetics of ranitidine in patients with renal failure. J Clin Pharmacol 1986, 26:286-291.
36. Shinn AF: Clinical relevance of cimetidine drug interactions. Drug Saf 1992, 7:245-267.
37. Somogyi A, Muirhead M: Pharmacokinetic interactions of cimetidine. Clin Pharmacokinet 1987, 12:321-366.
38. Hendeles L, Jenkins J, Temple R: Revised FDA labeling guideline for theophylline oral dosage forms. Pharmacotherapy 1995, 15:409-427.
39. Hamilton FA: Incidence and cost of hospital admissions secondary to drug interactions involving theophylline. Ann Pharmacother 1992, 26:1507-1511.
40. Britton ML, Waller ES: Central nervous system toxicity associated with concurrent use of triazolam and cimetidine. Drug Intell Clin Pharm 1985, 19:666-668.
41. Bauer LA, Black D, Gensler A: Procainamide-cimetidine drug interaction in elderly male patients. J Am Geriatr Soc 1990, 38: 467-469.
42. Feely J, Wilkinson GR, McAllister CB, Wood AJ: Increased toxicity and reduced clearance of lidocaine by cimetidine. Ann Intern Med 1982, 96:592-594.
43. Baciewicz AM, Baciewicz FA Jr: Effect of cimetidine and ranitidine on cardiovascular drugs. Am Heart J 1989, 118: 44-154.
44. Richards DA: Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. J Clin Gastroenterol 1983, 5 Suppl 1:81-90.
45. Kirch W, Hoensch H, Janisch HD: Interactions and non-interactions with ranitidine. Clin Pharmacokinet 1984, 9: 93-510.
46. Murialdo G, Piovano PL, Costelli P, Fonzi S, Barberis A, Ghia M: Seizures during concomitant treatment with theophylline and ranitidine: a case report. Ann Ital Med Int 1990, 5:413.
47. Tse CST: Phenytoin concentration elevation subsequent to ranitidine administration. Ann Pharmacother 1993, 27: 448-1451.
48. Klotz U: Lack of effect of nizatidine on drug metabolism. Scand J Gastroenterol 1987, 136 Suppl:18-23.
49. Cournot A, Berlin I, Sallord JC, Singlas E: Lack of interaction between nizatidine and warfarin during chronic administration. J Clin Pharmacol 1988, 28:1120-1122.
50. Humphries TJ: Famotidine: a notable lack of drug interactions. Scand J Gastroenterol 1987, 134 Suppl:55-60.
51. Richter JE, Campbell DR, Kahrilas PJ, Huang B, Fludas C: Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med 2000, 160: 803-1809.
52. Agrawal NM, Campbell DR, Safdi MA, Lukasik NL, Huang B, Haber MM: Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Arch Intern Med 2000, 160:1455-1461.
53. Jansen JB, Van-Oene JC: Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. The Dutch Lansoprazole Study Group. Aliment Pharmacol Ther 1999, 13:1611-1620.
54. Kovacs TO, Wilcox CM, Devault K, Miska D, Bochenek W: Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study. Aliment Pharmacol Ther 2002, 16: 2043-2052.
55. Meneghelli UG, Boaventura S, Moraes-Filho JP, Leitao O, Ferrari AP, Almeida JR, Magalhaes AF, Castro LP, Haddad MT, Tolentino M et al.: Efficacy and tolerability of pantoprazole versus ranitidine in the treatment of reflux esophagitis and the influence of Helicobacter pylori infection on healing rate. Dis Esophagus 2002, 15:50-56.
56. Kaspari S, Biedermann A, Mey J: Comparison of pantoprazole 20 mg to ranitidine 150 mg b.i.d. in the treatment of mild gastroesophageal reflux disease. Digestion 2001, 63: 63-170.
57. van Zyl JH, de KG, van Rensburg CJ, Retief FJ, O'Keefe SJ, Theron I, Fischer R, Bethke T: Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux-oesophagitis: a randomized, double-blind, parallel, and multicentre study. Eur J Gastroenterol Hepatol 2000, 12: 97-202.
58. Meneghelli UG, Zaterka S, de Paula C, Malafaia O, Lyra LG: Pantoprazole versus ranitidine in the treatment of duodenal ulcer: a multicenter study in Brazil. Am J Gastroenterol 2000, 95: 2-66.
59. Mears JM, Kaplan B: Proton pump inhibitors: new drugs and indications. Am Fam Physician 1996, 53:285-292.
60. Garnett WR: Considerations for long-term use of proton-pump inhibitors. Am J Health Syst Pharm 1998, 55: 268-2279.
61. Freston JW: Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective. Am J Gastroenterol 1997, 92:51S-55S.
62. Phillips JO, Olsen KM, Rebuck JA, Rangneker NJ, Miedema BW, Metzler MH: A randomized, pharmacokinetic, and pharmacodynamic, cross-over study of duodenal or jejunal administration of omeprazole suspension in patients at risk for stress ulcers. Am J Gastroenterol 2001, 96:367-372.
63. Balaban DH, Duckworth CW, Peura DA: Nasogastric omeprazole: effects on gastric pH in critically ill patients. Am J Gastroenterol 1997, 92:79-83.
64. Levy MJ, Seelig CB, Robinson NJ, Ranney JE: Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci 1997, 42:1255-1259.
65. Roberts KW, Pitcher WD, Cryer B: Effects of lansoprazole suspension versus continuous intravenous ranitidine on gastric pH of mechanically ventilated intensive care unit patients [abstract]. Crit Care Med 2000, 28:A185.
66. Morris J, Karlstadt R, Blatcher D, Field D: Intermittent intravenous pantoprazole rapidly achieves and maintains gastric pH > 4.0 compared with continuous infusion H2-receptor antagonist in intensive care unit patients [abstract]. Crit Care Med 2001, 29: 147.
67. Phillips JO, Metzler MH, Palmieri TL, Huckfeldt RE, Dahl NG: A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med 1996, 24:1793-1800.
68. Lasky MR, Metzler MH, Phillips JO: A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. J Trauma 1998, 44:527-533.
69. Phillips JO, Metzler MH, Huckfeldt RE, Olsen K: A multicenter, prospective, randomized clinical trial of continuous infusion I.V. ranitidine vs omeprazole suspection in the prophylaxis of stress ulcers [abstract]. Crit Care Med 1998, 26:101A.
70. Cohen H, Baldwin SN, Mukherji R, Ramos L, Dasgupta S, DiGregorio RV, Popadopoulos J, Reilly J, Hayat L: A comparison of lansoprazole and sucralfate for the prophylaxis of stress-related mucosal damage in critically ill patients [abstract]. Crit Care Med 2000, 28:A185.
71. Laterre PF, Horsmans Y: Intravenous omeprazole in critically ill patients: a randomized, crossover study comparing 40 with 80 mg plus 8 mg/hour on intragastric pH. Crit Care Med 2001, 29:1931-1935.
72. Otani Y, Kitajima M, Sugiyama M, Watanabe Y, Aoki T: Inhibitory effects of intravenous lansoprazole on gastric acid hypersecretion in patients with postoperative stress. J Clin Gastroenterol 1995, 20 Suppl 2:S22-S26.
73. Huber R, Hartmann M, Bliesath H, Lühmann R, Steinijans VW, Zech K: Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996, 34:S7-S16.
74. Lins RL, De Clercq I, Hartmann M, Huber R, Bliesath H, Lühmann R, Wurst W: Pharmacokinetics of the proton pump inhibitor Pantoprazole in patients with severe renal impairment [abstract]. Gastroenterology 1994, 106 Suppl 4:A126.
75. Kliem V: Pharmacokinetics of pantoprazole in hemodialysis patients [abstract]. Kidney Int 1995, 47:984.
76. Cheer SM, Prakash A, Faulds D, Lamb HM: Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 2003, 63: 101-133.
77. Zech K, Steinijans VW, Huber R, Kolassa N, Radtke HW: Pharmacokinetics and drug interactions-relevant factors for the choice of a drug. Int J Clin Pharmacol Ther 1996, 34 Suppl:S3-S6.
78. Meyer UA: Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 1996, 8 Suppl 1:S21-S25.
79. Tucker GT: The interaction of proton pump inhibitors with cytochromes P450. Aliment Pharmacol Ther 1994, 8 Suppl 1: 33-38.
80. Kokufu T, Ihara N, Sugioka N, Koyama H, Ohta T, Mori S, Nakajima K: Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol 1995, 48: 391-395.
81. Granneman GR, Karol MD, Locke CS, Cavanaugh JH: Pharmacokinetic interaction between lansoprazole and theophylline. Ther Drug Monit 1995, 17:460-464.